Skip to main content

Advertisement

SpringerLink
Log in

Myocardial remodeling in low-renin hypertension: Molecular pathways to cellular injury in relative aldosteronism

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The pathologic hypertrophy of hypertensive heart disease is related to the quality, not the quantity, of myocardium; the presence of fibrosis is inevitably linked to structural and functional insufficiencies with increased cardiovascular risk. Elevations in plasma aldosterone that are inappropriate relative to dietary sodium, or relative aldosteronism, are accompanied by suppressed plasma renin activity, elevation in arterial pressure, and dyshomeostasis of divalent cations. The accompanying hypocalcemia, hypomagnesemia, and hypozincemia of aldosteronism contribute to the appearance of secondary hyperparathyroidism. Parathyroid hormone-mediated intracellular calcium overloading of cardiac myocytes and mitochondria leads to the induction of oxidative stress and molecular pathways associated with cardiomyocyte necrosis and scarring of myocardium, whereas the dyshomeostasis of zinc compromises antioxidant defenses. This dyshomeostasis of calcium and zinc, intrinsically coupling prooxidant calcium and antioxidant zinc, raises the prospect for therapeutic strategies designed to mitigate intracellular calcium overloading while enhancing zinc-mediated antioxidant defenses, thus preventing adverse myocardial remodeling with fibrosis, associated diastolic dysfunction, and cardiac arrhythmias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Julius S, Li Y, Brant D, et al.: Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension. Hypertension 1991, 17:1161–1166.

    CAS  PubMed  Google Scholar 

  2. Messerli FH, Grodzicki T: Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992, 13(Suppl D):66–69.

    PubMed  Google Scholar 

  3. Shapiro LM, McKenna WJ: Left ventricular hypertrophy: relation of structure to diastolic function in hypertension. Br Heart J 1984, 51:637–642.

    Article  CAS  PubMed  Google Scholar 

  4. Sugihara N, Genda A, Shimizu M, et al.: Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol 1988, 18:353–361.

    CAS  PubMed  Google Scholar 

  5. Díez J, Querejeta R, López B, et al.: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512–2517.

    Article  PubMed  CAS  Google Scholar 

  6. Ghali JK, Kadakia S, Cooper RS, Liao Y: Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991, 17:1277–1282.

    CAS  PubMed  Google Scholar 

  7. Cooper RS, Simmons BE, Castaner A, et al.: Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990, 65:441–445.

    Article  CAS  PubMed  Google Scholar 

  8. Pearlman ES, Weber KT, Janicki JS, et al.: Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982, 46:158–164.

    CAS  PubMed  Google Scholar 

  9. Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F: Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract 1989, 184:577–581.

    CAS  PubMed  Google Scholar 

  10. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998, 16:1031–1041.

    Article  CAS  PubMed  Google Scholar 

  11. Cooper RS, Ghali JK: Coronary heart disease: blackwhite differences. In Cardiovascular Diseases in Blacks. Edited by Saunders E. Philadelphia: F. A. Davis; 1991:205–225.

    Google Scholar 

  12. Ghali JK, Kadakia S, Cooper R, Ferlinz J: Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 1988, 148:2013–2016.

    Article  CAS  PubMed  Google Scholar 

  13. Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441–449.

    Article  CAS  PubMed  Google Scholar 

  14. Williams GH, Cain JP, Dluhy RG, Underwood RH: Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest 1972, 51:1731–1742.

    Article  CAS  PubMed  Google Scholar 

  15. Collins RD, Weinberger MH, Dowdy AJ, et al.: Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity. J Clin Invest 1970, 49:1415–1426.

    Article  CAS  PubMed  Google Scholar 

  16. Williams GH, Hollenberg NK: Functional derangements in the regulation of aldosterone secretion in hypertension. Hypertension 1991, 18:III143–III149.

    CAS  PubMed  Google Scholar 

  17. Resnick LM, Müller FB, Laragh JH: Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986, 105:649–654.

    CAS  PubMed  Google Scholar 

  18. Rossi E, Sani C, Perazzoli F, et al.: Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995, 8:884–893.

    Article  CAS  PubMed  Google Scholar 

  19. Bell NH, Greene A, Epstein S, et al.: Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985, 76:470–473.

    Article  CAS  PubMed  Google Scholar 

  20. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, et al.: Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol 2002, 57:51–55.

    CAS  PubMed  Google Scholar 

  21. Alsafwah S, LaGuardia SP, Nelson MD, et al.: Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci 2008, 335:292–297.

    Article  PubMed  Google Scholar 

  22. Horton R, Biglieri EG: Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab 1962, 22:1187–1192.

    Article  CAS  PubMed  Google Scholar 

  23. Conn JW: Aldosteronism in man. Some clinical and climatological aspects. Part II. JAMA 1963, 183:871–878.

    CAS  PubMed  Google Scholar 

  24. Garcia Zozaya JL, Padilla Viloria M: [Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-aldosterone system] [Spanish]. Invest Clin 1997, 38(Suppl 2):27–40.

    PubMed  Google Scholar 

  25. Tubek S: Zinc content in lymphocytes and the activity of zinc ion efflux from lymphocytes in primary arterial hypertension. Biol Trace Elem Res 2005, 107:89–99.

    Article  CAS  PubMed  Google Scholar 

  26. Cohen AJ, Roe FJ: Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol 2000, 38:237–253.

    Article  CAS  PubMed  Google Scholar 

  27. Fleckenstein A: [Metabolic problems in myocardium insufficiency] [German]. Verh Dtsch Ges Pathol 1967, 51:15–30.

    CAS  PubMed  Google Scholar 

  28. Fujita T, Palmieri GM: Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab 2000, 18:109–125.

    Article  CAS  PubMed  Google Scholar 

  29. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994, 14:219–231.

    CAS  PubMed  Google Scholar 

  30. Smogorzewski M, Zayed M, Zhang YB, et al.: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 1993, 264:H1998–H2006.

    CAS  PubMed  Google Scholar 

  31. Rampe D, Lacerda AE, Dage RC, Brown AM: Parathyroid hormone: an endogenous modulator of cardiac calcium channels. Am J Physiol 1991, 261(6 Pt 2):H1945–H1950.

    CAS  PubMed  Google Scholar 

  32. Tastan I, Schreckenberg R, Mufti S, et al.: Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a nonacute way. Cardiovasc Res 2009, 82:77–83.

    Article  CAS  PubMed  Google Scholar 

  33. Virdis A, Neves MF, Amiri F, et al.: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002, 40:504–510.

    Article  CAS  PubMed  Google Scholar 

  34. Pu Q, Neves MF, Virdis A, et al.: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003, 42:49–55.

    Article  CAS  PubMed  Google Scholar 

  35. Sun Y, Zhang J, Lu L, et al.: Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002, 161:1773–1781.

    CAS  PubMed  Google Scholar 

  36. Gerling IC, Sun Y, Ahokas RA, et al.: Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003, 285:H813–H821.

    CAS  PubMed  Google Scholar 

  37. McCarron DA, Pingree PA, Rubin RJ, et al.: Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension 1980, 2:162–168.

    CAS  PubMed  Google Scholar 

  38. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41–46.

    Article  PubMed  Google Scholar 

  39. Okin PM, Devereux RB, Harris KE, et al.: Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007, 147:311–319.

    PubMed  Google Scholar 

  40. Okin PM, Devereux RB, Jern S, et al.: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292:2343–2349.

    Article  CAS  PubMed  Google Scholar 

  41. Julius S, Alderman MH, Beevers G, et al.: Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004, 43:1047–1055.

    Article  PubMed  Google Scholar 

  42. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990, 67:1355–1364.

    CAS  PubMed  Google Scholar 

  43. Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138–147.

    Article  CAS  PubMed  Google Scholar 

  44. Schiffrin EL: Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995, 25:1135–1143.

    CAS  PubMed  Google Scholar 

  45. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689–1697.

    Article  CAS  PubMed  Google Scholar 

  46. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578–2583.

    Article  CAS  PubMed  Google Scholar 

  47. Garnier A, Bendall JK, Fuchs S, et al.: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004, 110:1819–1825.

    Article  CAS  PubMed  Google Scholar 

  48. Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101:1722–1728.

    CAS  PubMed  Google Scholar 

  49. Gandhi MS, Deshmukh PA, Kamalov G, et al.: Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol 2008, 52:245–252.

    Article  CAS  PubMed  Google Scholar 

  50. Fleckenstein A, Frey M, Fleckenstein-Grun G: Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J 1983, 4(Suppl H):43–50.

    CAS  PubMed  Google Scholar 

  51. Chhokar VS, Sun Y, Bhattacharya SK, et al.: Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005, 111:871–878.

    Article  CAS  PubMed  Google Scholar 

  52. Ahokas RA, Sun Y, Bhattacharya SK, et al.: Aldosteronism and a proinflammatory vascular phenotype. Role of Mg2+, Ca2+ and H2O2 in peripheral blood mononuclear cells. Circulation 2005, 111:51–57.

    Article  CAS  PubMed  Google Scholar 

  53. Ahokas RA, Warrington KJ, Gerling IC, et al.: Aldosteronism and peripheral blood mononuclear cell activation. A neuro endocrine-immune interface. Circ Res 2003, 93:e124–e135.

    Article  CAS  PubMed  Google Scholar 

  54. Chhokar VS, Sun Y, Bhattacharya SK, et al.: Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004, 287:H2023–H2026.

    Article  CAS  PubMed  Google Scholar 

  55. McCarron DA, Morris CD, Bukoski R: The calcium paradox of essential hypertension. Am J Med 1987, 82:27–33.

    Article  CAS  PubMed  Google Scholar 

  56. Goodwin KD, Ahokas RA, Bhattacharya SK, et al.: Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci 2006, 332:73–78.

    Article  PubMed  Google Scholar 

  57. Vidal A, Sun Y, Bhattacharya SK, et al.: Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006, 290:H286–H294.

    Article  CAS  PubMed  Google Scholar 

  58. Selektor Y, Ahokas RA, Bhattacharya SK, et al.: Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci 2008, 335:105–110.

    Article  PubMed  Google Scholar 

  59. Thomas M, Vidal A, Bhattacharya SK, et al.: Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol 2007, 293:H2361–H2366.

    Article  CAS  PubMed  Google Scholar 

  60. Selektor Y, Parker RB, Sun Y, et al.: Tissue 65Zinc translocation in a rat model of chronic aldosteronism. J Cardiovasc Pharmacol 2008, 51:359–364.

    Article  CAS  PubMed  Google Scholar 

  61. Aureli L, Gioia M, Cerbara I, et al.: Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr Med Chem 2008, 15:2192–2222.

    Article  CAS  PubMed  Google Scholar 

  62. Kamalov G, Deshmukh PA, Baburyan NY, et al.: Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol 2009, 53:414–423.

    Article  CAS  PubMed  Google Scholar 

  63. Wang J, Song Y, Elsherif L, et al.: Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113:544–554.

    Article  CAS  PubMed  Google Scholar 

  64. Karagulova G, Yue Y, Moreyra A, et al.: Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. J Pharmacol Exp Ther 2007, 321:517–525.

    Article  CAS  PubMed  Google Scholar 

  65. Chvapil M, Owen JA: Effect of zinc on acute and chronic isoproterenol induced heart injury. J Mol Cell Cardiol 1977, 9:151–159.

    Article  CAS  PubMed  Google Scholar 

  66. Palmieri GM, Nutting DF, Bhattacharya SK, et al.: Parathyroid ablation in dystrophic hamsters. Effects on Ca content and histology of heart, diaphragm, and rectus femoris. J Clin Invest 1981, 68:646–654.

    Article  CAS  PubMed  Google Scholar 

  67. Bhattacharya SK, Palmieri GM, Bertorini TE, Nutting DF: The effects of diltiazem in dystrophic hamsters. Muscle Nerve 1982, 5:73–78.

    Article  CAS  PubMed  Google Scholar 

  68. Crawford AJ, Bhattacharya SK: Excessive intracellular zinc accumulation in cardiac and skeletal muscles of dystrophic hamsters. Exp Neurol 1987, 95:265–276.

    Article  CAS  PubMed  Google Scholar 

  69. Díez J: Towards a new paradigm about hypertensive heart disease. Med Clin North Am 2009, 93:637–645.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, University of Tennessee Health Science Center, 956 Court Avenue, Suite A312, Memphis, TN, 38163, USA

    Karl T. Weber

Authors
  1. Syamal K. Bhattacharya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malay S. Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. German Kamalov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert A. Ahokas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ivan C. Gerling
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karl T. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl T. Weber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhattacharya, S.K., Gandhi, M.S., Kamalov, G. et al. Myocardial remodeling in low-renin hypertension: Molecular pathways to cellular injury in relative aldosteronism. Current Science Inc 11, 412–420 (2009). https://doi.org/10.1007/s11906-009-0071-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0071-0

Keywords

Search

Navigation